Vimarsana
Biggest News Aggregation in the World

Page 6 - Ophthalmic Solution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ophthalmic Solution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ophthalmic Solution Today - Breaking & Trending Today

Antiglaucoma Drugs Global Market Report 2023 - Vimarsana News

Antiglaucoma Drugs Global Market Report 2023

/PRNewswire/ -- Major players in the antiglaucoma drugs market are Aerie Pharmaceuticals, Inc., Allergan, Novartis AG, Abbott Healthcare, Johnson & Johnson,...

Bausch + Lomb Corporation: Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology - Vimarsana News

Bausch + Lomb Corporation: Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

NOV03 is Being Investigated to Treat the Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction NOV03 PDUFA Action Date is June 28, 2023 Bausch Lomb Corporation (NYSE/TSX:

Prasco Launches Authorized Generic of ZIOPTAN® Ophthalmic Solution - Vimarsana News

Prasco Launches Authorized Generic of ZIOPTAN® Ophthalmic Solution

/PRNewswire/ -- Prasco Laboratories announced today the launch of the Authorized Generic of ZIOPTAN® (tafluprost ophthalmic solution) 0.0015%. This is Prasco's...

Dompé announces first patient enrolled in Phase 3 trial of cenegermin in patients with severe Sjögren's-related dry eye disease - Vimarsana News

Dompé announces first patient enrolled in Phase 3 trial of cenegermin in patients with severe Sjögren's-related dry eye disease

MILAN, Italy and SAN MATEO, Calif, Feb. 9, 2022 /PRNewswire/ -- Dompé farmaceutici S.p.A. and Dompé U.S. Inc. (collectively Dompé) announced today...

Dompé announces first patient enrolled in Phase 3 trial of cenegermin in patients with severe Sjögren's-related dry eye disease - Vimarsana News

Dompé announces first patient enrolled in Phase 3 trial of cenegermin in patients with severe Sjögren's-related dry eye disease

/PRNewswire/ -- Dompé farmaceutici S.p.A. and Dompé U.S. Inc. (collectively Dompé) announced today that the first patient has been enrolled in its Phase 3...